Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botulinum A toxin versus anticholinergic therapy for overactive bladder
IRCT20120215009014N488Phase 3Completed
- Sponsor
- Hamadan University of Medical Sciences
- Start
- Nov 2023
- Modality
- Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of botulinum toxin type A, solifenacin, oxybutynin and cefazolin in overactive bladder (OAB) (2 arms), sponsored by Hamadan University of Medical Sciences. Primary endpoint: Severity of clinical symptoms. Started Nov 2023; status: completed.
02
Drugs
botulinum toxin type Asolifenacinoxybutynincefazolin
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on IRCT20120215009014N488.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20120215009014N488.